199 related articles for article (PubMed ID: 24036490)
21. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist.
LaMoreaux B; Barbar-Smiley F; Ardoin S; Madhoun H
Semin Arthritis Rheum; 2016 Feb; 45(4):e10-2. PubMed ID: 26329147
[TBL] [Abstract][Full Text] [Related]
22. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Le Rhun E; Devos P; Houillier C; Cartalat S; Chinot O; Di Stefano AL; Lepage C; Reyns N; Dubois F; Weller M
Neurology; 2019 Nov; 93(19):e1799-e1806. PubMed ID: 31586022
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
24. Thrombopoietin-receptor agonists for immune thrombocytopenia.
Jansen AJ; Swart RM; te Boekhorst PA
N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
[No Abstract] [Full Text] [Related]
25. The development of romiplostim for patients with immune thrombocytopenia.
Molineux G
Ann N Y Acad Sci; 2011 Mar; 1222():55-63. PubMed ID: 21434943
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
27. Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim.
Thachil J; Salter I; George JN
Eur J Haematol; 2013 Oct; 91(4):376-7. PubMed ID: 23822831
[No Abstract] [Full Text] [Related]
28. Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia.
Sinisalo M; Sankelo M; Itälä-Remes M
Leuk Lymphoma; 2011 Apr; 52(4):724-5. PubMed ID: 21323511
[No Abstract] [Full Text] [Related]
29. Treatment of chronic immune thrombocytopenia in children with romiplostim.
Chaturvedi S; McCrae KR
Lancet; 2016 Jul; 388(10039):4-6. PubMed ID: 27103125
[No Abstract] [Full Text] [Related]
30. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.
Hartranft ME; Clemmons AB; DeRemer DL; Kota V
J Oncol Pharm Pract; 2017 Jan; 23(1):10-17. PubMed ID: 26471738
[TBL] [Abstract][Full Text] [Related]
32. Remissions after long-term use of romiplostim for immune thrombocytopenia.
Marshall AL; Scarpone R; De Greef M; Bird R; Kuter DJ
Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
[No Abstract] [Full Text] [Related]
33. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.
Michel M; te Boekhorst PA; Janssens A; Pabinger-Fasching I; Sanz MA; Nie K; Kreuzbauer G
Hematology; 2011 Sep; 16(5):274-7. PubMed ID: 21902890
[TBL] [Abstract][Full Text] [Related]
34. Romiplostim resistance in secondary failure of platelet recovery.
DeRemer DL; Katsanevas K; Bradley A; Awan FT
J Oncol Pharm Pract; 2013 Dec; 19(4):369-72. PubMed ID: 23292974
[TBL] [Abstract][Full Text] [Related]
35. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia.
D'Arena G; Cascavilla N
Leuk Lymphoma; 2011 Apr; 52(4):701-4. PubMed ID: 21171868
[No Abstract] [Full Text] [Related]
36. Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy.
Decroocq J; Marcellin L; Le Ray C; Willems L
Obstet Gynecol; 2014 Aug; 124(2 Pt 2 Suppl 1):481-483. PubMed ID: 25004319
[TBL] [Abstract][Full Text] [Related]
37. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
[TBL] [Abstract][Full Text] [Related]
38. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
[No Abstract] [Full Text] [Related]
39. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
40. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
